Similar articles

• Reflection on the selection of doses of arenobufagin in vivo anticancer study.

  Chen L, Zhang D. Chen L, et al. Pharmacol Res. 2018 Feb;128:402. doi: 10.1016/j.phrs.2017.09.016. Epub 2017 Oct 5. Pharmacol Res. 2018. PMID: 28987597 No abstract available.
• Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis.

  Gao F, Alwhaibi A, Sabbineni H, Verma A, Eldahshan W, Somanath PR. Gao F, et al. Cancer Lett. 2017 Aug 28;402:177-189. doi: 10.1016/j.canlet.2017.05.028. Epub 2017 Jun 7. Cancer Lett. 2017. PMID: 28602980 Free PMC article.
• Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway.

  Li H, Huang J, Yang B, Xiang T, Yin X, Peng W, Cheng W, Wan J, Luo F, Li H, Ren G. Li H, et al. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):180-90. doi: 10.1016/j.taap.2013.05.011. Epub 2013 May 22. Toxicol Appl Pharmacol. 2013. PMID: 23707762
• Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process.

  Lee HM, Hwang KA, Choi KC. Lee HM, et al. Mol Cell Endocrinol. 2017 Dec 5;457:103-113. doi: 10.1016/j.mce.2016.12.026. Epub 2016 Dec 29. Mol Cell Endocrinol. 2017. PMID: 28042023 Review.
• Epithelial-mesenchymal transition in prostate cancer: an overview.

  Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E, Iovane G, Piscitelli R, Muscariello R, Berretta M, Perdonà S, Muto P, Botti G, Bianchi AAM, Veneziani BM, Facchini G. Montanari M, et al. Oncotarget. 2017 May 23;8(21):35376-35389. doi: 10.18632/oncotarget.15686. Oncotarget. 2017. PMID: 28430640 Free PMC article. Review.